Publications

Sarapulov AV, Rodriguez M-A, Zappasodi R.  2026.  Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells.. Methods Cell Biol. 202:253-276.

Serganova I, Colombo G, Ballesio F, Kang JHye, Karakousi T, Esposito TVF, Ackerstaff E, Santella A, Blasberg R, Pillarsetty NVara Kisho et al..  2026.  A tumor metabolism-angiogenesis-immune axis governs immunotherapy responses.. bioRxiv.

Cancila V, Bertolazzi G, Chan ASy, Medico G, Bastianello G, Morello G, Paysan D, Lai C, Hong L, Shenoy G et al..  2025.  Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.. J Clin Invest. 135(18)

Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J et al..  2025.  EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.. Cancer Cell. 43(1):49-68.e9.

Hamid O, Cardin DB, F Hodi S, LoRusso P, Merghoub T, Zappasodi R, Maniyar R, Janik JE, van der Velden MVW, Zhou F et al..  2025.  First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.. Clin Cancer Res.

Weng C-H, Assouvie A, Dong L, Beltra J-C, Budhu S, Mangarin L, Marouf Y, Morgado-Palacin L, Liu C, Monette S et al..  2025.  Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.. Nat Immunol. 26(12):2296-2311.

Devarajan P, Zappasodi R, Pishesha N, Weng J-H, Alexander K, Soto-Feliciano Y, Kedmi R.  2025.  Women in STEM becoming independent: Put science and discovery ahead of your ego.. J Exp Med. 222(11)

Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao Z-K, Ouerfelli O, Liu H et al..  2024.  APR-246 increases tumor antigenicity independent of p53.. Life Sci Alliance. 7(1)

Li J, Chin CR, Ying H-Y, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu C-S, Jiang Y et al..  2024.  Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.. Nat Commun. 15(1):2879.

Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, Bah MA, Assouvie A, Marouf Y, Schulze I et al..  2024.  Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.. J Clin Invest. 134(17)

Kang JHye, Zappasodi R.  2023.  Modulating Treg stability to improve cancer immunotherapy.. Trends Cancer. 9(11):911-927.

Kluger H, J Barrett C, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H et al..  2023.  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.. J Immunother Cancer. 11(3)

Davar D, Zappasodi R.  2023.  Targeting GITR in cancer immunotherapy - there is no perfect knowledge.. Oncotarget. 14:614-621.

Gregucci F, Spada S, Barcellos-Hoff MHelen, Bhardwaj N, Hak CChan Wah, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG et al..  2023.  Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.. Oncoimmunology. 12(1):2222560.

Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CCimen, Mangarin LMB, Redmond D, Verma S, Schad S et al..  2022.  Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.. Sci Transl Med. 14(649):eaba4380.

Huang AC, Zappasodi R.  2022.  A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.. Nat Immunol. 23(5):660-670.

Zappasodi R, Cook GP, Taylor A.  2022.  Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy.. Front Immunol. 13:1120207.

Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E.  2022.  Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.. Front Oncol. 12:1061789.

Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KCésar, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR et al..  2022.  Fundamental immune-oncogenicity trade-offs define driver mutation fitness.. Nature. 606(7912):172-179.

Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL, Horak CE et al..  2022.  Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. Cancer Immunol Res. 10(4):372-383.

Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho Y-J, Campesato LFelipe, Mangarin L et al..  2022.  Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.. J Clin Invest. 132(18)

Andrlová H, Miltiadous O, Kousa AI, Dai A, DeWolf S, Violante S, Park H-Y, Janaki-Raman S, Gardner R, Daker SEl et al..  2022.  MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT.. Sci Transl Med. 14(646):eabj2829.

Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J et al..  2022.  Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.. Clin Cancer Res. 28(18):3990-4002.

He C, Maniyar RR, Avraham Y, Zappasodi R, Rusinova R, Newman W, Heath H, Wolchok JD, Dahan R, Merghoub T et al..  2022.  Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.. Sci Adv. 8(8):eabm4552.

Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M et al..  2022.  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.. J Exp Med. 219(6)